JP5128578B2 - 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 - Google Patents
解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 Download PDFInfo
- Publication number
- JP5128578B2 JP5128578B2 JP2009503576A JP2009503576A JP5128578B2 JP 5128578 B2 JP5128578 B2 JP 5128578B2 JP 2009503576 A JP2009503576 A JP 2009503576A JP 2009503576 A JP2009503576 A JP 2009503576A JP 5128578 B2 JP5128578 B2 JP 5128578B2
- Authority
- JP
- Japan
- Prior art keywords
- opioid receptor
- alkyl
- receptor antagonist
- disorders
- dissociative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 239000002618 kappa opiate receptor antagonist Substances 0.000 title claims description 17
- 208000018459 dissociative disease Diseases 0.000 title abstract description 21
- 238000011282 treatment Methods 0.000 title abstract description 11
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims abstract description 23
- 208000022821 personality disease Diseases 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 19
- 150000002148 esters Chemical class 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- 239000003401 opiate antagonist Substances 0.000 claims description 8
- 230000002996 emotional effect Effects 0.000 claims description 5
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 3
- 229960004127 naloxone Drugs 0.000 claims description 3
- 102000048260 kappa Opioid Receptors Human genes 0.000 abstract description 15
- 108020001588 κ-opioid receptors Proteins 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 20
- 229960001736 buprenorphine Drugs 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 13
- 239000005557 antagonist Substances 0.000 description 10
- 150000002170 ethers Chemical class 0.000 description 10
- 150000004677 hydrates Chemical class 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 206010054196 Affect lability Diseases 0.000 description 5
- 206010034719 Personality change Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 208000028173 post-traumatic stress disease Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 4
- 208000030990 Impulse-control disease Diseases 0.000 description 4
- 102000003840 Opioid Receptors Human genes 0.000 description 4
- 108090000137 Opioid Receptors Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 206010016754 Flashback Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- -1 C 1-8 -alkyl Chemical class 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 208000001836 Firesetting Behavior Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010037180 Psychiatric symptoms Diseases 0.000 description 2
- 208000033712 Self injurious behaviour Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SFNLWIKOKQVFPB-KZCPYJDTSA-N bunavail Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C.C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 SFNLWIKOKQVFPB-KZCPYJDTSA-N 0.000 description 2
- 229940086585 buprenorphine 12 mg Drugs 0.000 description 2
- 229940114081 cinnamate Drugs 0.000 description 2
- 208000012839 conversion disease Diseases 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- LOYWOYCPSWPKFH-DSNGMDLFSA-N quadazocine Chemical compound C([C@]1(C)[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2C)CC(=O)CCC1CCCC1 LOYWOYCPSWPKFH-DSNGMDLFSA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- XHNRBXWASNDLFT-CMPLNLGQSA-N 3-[(2s,4r)-1,2-dimethylpiperidin-4-yl]phenol Chemical compound C1CN(C)[C@@H](C)C[C@@H]1C1=CC=CC(O)=C1 XHNRBXWASNDLFT-CMPLNLGQSA-N 0.000 description 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- RWKGLHPVZHKSRY-CLUYDPBTSA-N C1=CC=C2NC=CC2=C1.C1CCC[C@H]2[C@]3([H])NCC[C@@]21C1=CC=CC=C1C3 Chemical class C1=CC=C2NC=CC2=C1.C1CCC[C@H]2[C@]3([H])NCC[C@@]21C1=CC=CC=C1C3 RWKGLHPVZHKSRY-CLUYDPBTSA-N 0.000 description 1
- 0 CC(C)C(CN(CC1)C*C1(C)C(C1)C=CC=C1O*)NC(CC(*)Cc1c(*)cc(*)cc1)=O Chemical compound CC(C)C(CN(CC1)C*C1(C)C(C1)C=CC=C1O*)NC(CC(*)Cc1c(*)cc(*)cc1)=O 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 206010021567 Impulsive behaviour Diseases 0.000 description 1
- 206010022524 Intentional self-injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006389 acute stress response Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940056146 buprenorphine / naloxone Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 206010013461 dissociative amnesia Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 239000004407 iron oxides and hydroxides Substances 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 1
- 239000002623 mu opiate receptor antagonist Substances 0.000 description 1
- 229940048432 naloxone 2 mg Drugs 0.000 description 1
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940070721 polyacrylate Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000010346 psychosocial stress Effects 0.000 description 1
- 125000004309 pyranyl group Chemical class O1C(C=CC=C1)* 0.000 description 1
- 229950000368 quadazocine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006015733.8 | 2006-04-04 | ||
| DE102006015733A DE102006015733A1 (de) | 2006-04-04 | 2006-04-04 | Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit |
| DE102006016991.3 | 2006-04-11 | ||
| DE102006016991A DE102006016991A1 (de) | 2006-04-11 | 2006-04-11 | Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen |
| PCT/EP2007/053248 WO2007115975A2 (de) | 2006-04-04 | 2007-04-03 | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009532434A JP2009532434A (ja) | 2009-09-10 |
| JP2009532434A5 JP2009532434A5 (OSRAM) | 2010-11-11 |
| JP5128578B2 true JP5128578B2 (ja) | 2013-01-23 |
Family
ID=38110094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503576A Expired - Fee Related JP5128578B2 (ja) | 2006-04-04 | 2007-04-03 | 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8063059B2 (OSRAM) |
| EP (1) | EP2001456B1 (OSRAM) |
| JP (1) | JP5128578B2 (OSRAM) |
| AT (1) | ATE450256T1 (OSRAM) |
| AU (1) | AU2007236003B2 (OSRAM) |
| CA (1) | CA2646899C (OSRAM) |
| CY (1) | CY1109862T1 (OSRAM) |
| DE (1) | DE502007002185D1 (OSRAM) |
| DK (1) | DK2001456T3 (OSRAM) |
| EA (1) | EA014820B1 (OSRAM) |
| ES (1) | ES2337622T3 (OSRAM) |
| HR (1) | HRP20100113T1 (OSRAM) |
| PL (1) | PL2001456T3 (OSRAM) |
| PT (1) | PT2001456E (OSRAM) |
| RS (1) | RS51211B (OSRAM) |
| SI (1) | SI2001456T1 (OSRAM) |
| WO (1) | WO2007115975A2 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101925576B (zh) | 2008-01-22 | 2013-02-06 | 伊莱利利公司 | κ-选择性阿片受体拮抗剂 |
| CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| JP6448645B2 (ja) * | 2013-12-20 | 2019-01-09 | ハー・ルンドベック・アクチエゼルスカベット | メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用 |
| PT3137081T (pt) | 2014-04-28 | 2018-02-08 | Orphomed Inc | Dímero de buprenorfina e o seu uso no tratamento de transtornos gastrointestinais |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| EP4489730A1 (en) | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| JP2025508051A (ja) | 2022-03-07 | 2025-03-21 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 大うつ病性障害の治療に使用するためのアチカプラントの多形形態 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028612A (en) | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5780479A (en) * | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
| AU2981099A (en) * | 1998-03-09 | 1999-09-27 | Trustees Of Tufts College | Treatment of compulsive behaviours in man and animals |
| EP1365756A2 (en) * | 2000-08-15 | 2003-12-03 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US6528518B2 (en) | 2000-12-21 | 2003-03-04 | The Mclean Hospital Corporation | Treatment of depression with kappa receptor antagonists |
| US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| EP1613617A4 (en) * | 2003-04-04 | 2009-02-18 | Merck & Co Inc | METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS |
| JP2007526328A (ja) | 2004-03-02 | 2007-09-13 | ファルマシア コーポレーション | 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物 |
| ME01072B (me) * | 2004-05-26 | 2012-10-20 | Inotek Pharmaceuticals Corp | Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu |
| EP1750675B1 (en) * | 2004-06-02 | 2008-10-29 | Galephar M/F | Stable oral pharmaceutical compositions of buprenorphine and salt thereof |
-
2007
- 2007-04-03 DK DK07727719.2T patent/DK2001456T3/da active
- 2007-04-03 WO PCT/EP2007/053248 patent/WO2007115975A2/de not_active Ceased
- 2007-04-03 DE DE502007002185T patent/DE502007002185D1/de active Active
- 2007-04-03 CA CA2646899A patent/CA2646899C/en not_active Expired - Fee Related
- 2007-04-03 HR HR20100113T patent/HRP20100113T1/hr unknown
- 2007-04-03 EP EP07727719A patent/EP2001456B1/de active Active
- 2007-04-03 EA EA200802104A patent/EA014820B1/ru not_active IP Right Cessation
- 2007-04-03 PL PL07727719T patent/PL2001456T3/pl unknown
- 2007-04-03 JP JP2009503576A patent/JP5128578B2/ja not_active Expired - Fee Related
- 2007-04-03 AT AT07727719T patent/ATE450256T1/de active
- 2007-04-03 RS RSP-2010/0089A patent/RS51211B/sr unknown
- 2007-04-03 ES ES07727719T patent/ES2337622T3/es active Active
- 2007-04-03 PT PT07727719T patent/PT2001456E/pt unknown
- 2007-04-03 US US12/296,125 patent/US8063059B2/en not_active Expired - Fee Related
- 2007-04-03 SI SI200730163T patent/SI2001456T1/sl unknown
- 2007-04-03 AU AU2007236003A patent/AU2007236003B2/en not_active Ceased
-
2010
- 2010-02-25 CY CY20101100188T patent/CY1109862T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007236003B2 (en) | 2012-10-18 |
| CY1109862T1 (el) | 2014-09-10 |
| US8063059B2 (en) | 2011-11-22 |
| EA200802104A1 (ru) | 2009-04-28 |
| ES2337622T3 (es) | 2010-04-27 |
| PT2001456E (pt) | 2010-03-03 |
| DK2001456T3 (da) | 2010-04-12 |
| WO2007115975A3 (de) | 2008-02-14 |
| SI2001456T1 (sl) | 2010-04-30 |
| AU2007236003A1 (en) | 2007-10-18 |
| EP2001456A2 (de) | 2008-12-17 |
| WO2007115975A2 (de) | 2007-10-18 |
| CA2646899A1 (en) | 2007-10-18 |
| EA014820B1 (ru) | 2011-02-28 |
| ATE450256T1 (de) | 2009-12-15 |
| CA2646899C (en) | 2014-05-06 |
| JP2009532434A (ja) | 2009-09-10 |
| PL2001456T3 (pl) | 2010-05-31 |
| HRP20100113T1 (hr) | 2010-04-30 |
| US20090181999A1 (en) | 2009-07-16 |
| EP2001456B1 (de) | 2009-12-02 |
| DE502007002185D1 (de) | 2010-01-14 |
| RS51211B (sr) | 2010-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5128578B2 (ja) | 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 | |
| US10952976B2 (en) | Compositions and methods for treating respiratory depression with fenfluramine | |
| HU202108B (en) | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol | |
| KR20130043217A (ko) | 덱스트로메토르판 및 퀴니딘을 포함하는 신경계 장애의 치료를 위한 약학적 조성물 | |
| CN104853755B (zh) | 包含沃替西汀和多奈哌齐的组合物 | |
| CN109640998A (zh) | 治疗昼夜节律性睡眠障碍的方法 | |
| JP7108041B2 (ja) | 睡眠障害の治療及び予防 | |
| Barth et al. | Anaphylactoid reactions and histamine release do not occur after application of the opioid tramadol | |
| JP4718771B2 (ja) | 本態性振戦の予防・治療剤 | |
| CN101677998B (zh) | 包含西洛他唑的治疗精神分裂症药物 | |
| TW200528098A (en) | Treatment of insomnia in human patients | |
| JP2007519709A (ja) | 神経接続欠陥、例えば精神分裂病及び自閉症の治療においてエポチロン（ｅｐｏｔｈｉｌｏｎｅ）を使用する方法 | |
| EP3130339B1 (en) | A compound for use in the treatment of comorbid anxiety disorder and depression disorder | |
| RU2820449C2 (ru) | Анальгезирующие композиции | |
| JP7406266B2 (ja) | 鎮痛組成物 | |
| JP2020517730A (ja) | 心的外傷後ストレス障害を治療するための方法 | |
| CZ300781B6 (cs) | Použití R-(+)-alfa-(2,3-dimethoxyfenyl)-1-[2-(4-fluorfenyl)ethyl]-4-piperidinmethanolu pro lécení poruch spánku | |
| HK1212601B (en) | Compositions comprising vortioxetine and donepezil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090626 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090626 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100323 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100323 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100909 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120612 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120807 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121002 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121031 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151109 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |